Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.
about
Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1H-indol-2-yl)methanols as Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against γ-Thrombin.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Development of a Series of (1- ...... d Activity Against γ-Thrombin.
@en
Development of a Series of
@nl
type
label
Development of a Series of (1- ...... d Activity Against γ-Thrombin.
@en
Development of a Series of
@nl
prefLabel
Development of a Series of (1- ...... d Activity Against γ-Thrombin.
@en
Development of a Series of
@nl
P2093
P2860
P1476
Development of a Series of (1- ...... d Activity Against γ-Thrombin.
@en
P2093
Anna L Blobaum
Heidi E Hamm
Jae G Maeng
Kayla J Temple
Matthew T Duvernay
Shaun R Stauffer
Summer E Young
Wandong Wen
P2860
P304
P356
10.1021/ACS.JMEDCHEM.6B00928
P407
P577
2016-08-02T00:00:00Z